Matches in SemOpenAlex for { <https://semopenalex.org/work/W2969132911> ?p ?o ?g. }
- W2969132911 endingPage "107763" @default.
- W2969132911 startingPage "107763" @default.
- W2969132911 abstract "Primary open-angle glaucoma (POAG) is a leading cause of irreversible blindness, and individuals with ocular hypertension are at risk to develop POAG. Currently, the only modifiable risk factor for glaucoma progression is lowering of intraocular pressure (IOP). A novel mechanism for lowering IOP involves activation of the type B natriuretic peptide receptor (NPR-B), the naturally occurring agonist of which is C-type natriuretic peptide (CNP). Being a cyclic peptide of 22 amino acids, CNP does not readily penetrate the cornea and its ocular hypotensive effect requires intraocular injection. TAK-639 is a synthetic, cornea-permeable, 9-amino acid CNP analog has been studied for the treatment of ocular hypertension and POAG. We assessed TAK-639 in a receptor binding profile and the effects of TAK-639 on NPR-B-mediated cyclic GMP production in cultured transformed human trabecular meshwork (TM) cells (GTM-3). We also evaluated the effects of topical ocular administration of TAK-639 on mouse IOP and aqueous humor dynamics. Among 89 non-natriuretic peptide receptors, transporters, and channels evaluated, TAK-639 at 10 μM displaced ligand binding by more than 50% to only two receptors: the type 2 angiotensin receptor (IC50 = 8.2 μM) and the cholecystokinin A receptor (IC50 = 25.8 μM). In vitro, TAK-639 selectively activates NPR-B (EC50 = 61 ± 11 nM; GTM-3 cells) relative to NPR-A (EC50 = 2179 ± 670 nM; 293T cells). In vivo, TAK-639 lowered mouse IOP by three mechanisms: increase in aqueous humor outflow facility (C), reduction in the aqueous humor formation rate (Fin), and reduction in episcleral venous pressure (Pe). The maximum mean IOP decreases from baseline were −12.1%, −21.0%, and −36.1% for 0.1%, 0.3%, and 0.6% doses of TAK-639, respectively. Maximum IOP-lowering effect was seen at 2 h, and the duration of action was >6 h. With TAK-639 0.6%, at 2 h post-dose, aqueous outflow facility (C) increased by 155.8%, Fin decreased by 41.0%, the uveoscleral outflow rate (Fu) decreased by 52.6%, and Pe decreased by 31.5% (all p < 0.05). No ocular adverse effects were observed. TAK-639 is an efficacious IOP-lowering agent, with a unique combination of mechanisms of action on both aqueous formation and aqueous outflow facility. Further study of this mechanism of treatment may optimize pharmacologic outcomes and provide disease management in patients with POAG and ocular hypertension." @default.
- W2969132911 created "2019-08-22" @default.
- W2969132911 creator A5007582903 @default.
- W2969132911 creator A5056800538 @default.
- W2969132911 creator A5061662773 @default.
- W2969132911 creator A5076507162 @default.
- W2969132911 date "2019-11-01" @default.
- W2969132911 modified "2023-09-30" @default.
- W2969132911 title "Effects of TAK-639, a novel topical C-type natriuretic peptide analog, on intraocular pressure and aqueous humor dynamics in mice" @default.
- W2969132911 cites W1409711228 @default.
- W2969132911 cites W1579903794 @default.
- W2969132911 cites W1967964182 @default.
- W2969132911 cites W1973235785 @default.
- W2969132911 cites W1979093057 @default.
- W2969132911 cites W1982751788 @default.
- W2969132911 cites W1983998901 @default.
- W2969132911 cites W1999521109 @default.
- W2969132911 cites W2001225968 @default.
- W2969132911 cites W2013340648 @default.
- W2969132911 cites W2019861198 @default.
- W2969132911 cites W2021586614 @default.
- W2969132911 cites W2027081380 @default.
- W2969132911 cites W2029574346 @default.
- W2969132911 cites W2034742711 @default.
- W2969132911 cites W2036115790 @default.
- W2969132911 cites W2043463661 @default.
- W2969132911 cites W2044268900 @default.
- W2969132911 cites W2047510146 @default.
- W2969132911 cites W2057266151 @default.
- W2969132911 cites W2060020138 @default.
- W2969132911 cites W2063829909 @default.
- W2969132911 cites W2065736920 @default.
- W2969132911 cites W2077340670 @default.
- W2969132911 cites W2088787853 @default.
- W2969132911 cites W2110614029 @default.
- W2969132911 cites W2120711134 @default.
- W2969132911 cites W2140594570 @default.
- W2969132911 cites W2159639769 @default.
- W2969132911 cites W2160292547 @default.
- W2969132911 cites W2160605010 @default.
- W2969132911 cites W2213028454 @default.
- W2969132911 cites W2276427070 @default.
- W2969132911 cites W2327563729 @default.
- W2969132911 cites W2788754665 @default.
- W2969132911 cites W2791105463 @default.
- W2969132911 cites W2027871852 @default.
- W2969132911 cites W2134517438 @default.
- W2969132911 doi "https://doi.org/10.1016/j.exer.2019.107763" @default.
- W2969132911 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31421135" @default.
- W2969132911 hasPublicationYear "2019" @default.
- W2969132911 type Work @default.
- W2969132911 sameAs 2969132911 @default.
- W2969132911 citedByCount "7" @default.
- W2969132911 countsByYear W29691329112020 @default.
- W2969132911 countsByYear W29691329112021 @default.
- W2969132911 countsByYear W29691329112022 @default.
- W2969132911 countsByYear W29691329112023 @default.
- W2969132911 crossrefType "journal-article" @default.
- W2969132911 hasAuthorship W2969132911A5007582903 @default.
- W2969132911 hasAuthorship W2969132911A5056800538 @default.
- W2969132911 hasAuthorship W2969132911A5061662773 @default.
- W2969132911 hasAuthorship W2969132911A5076507162 @default.
- W2969132911 hasBestOaLocation W29691329111 @default.
- W2969132911 hasConcept C118487528 @default.
- W2969132911 hasConcept C126322002 @default.
- W2969132911 hasConcept C134018914 @default.
- W2969132911 hasConcept C150903083 @default.
- W2969132911 hasConcept C170493617 @default.
- W2969132911 hasConcept C185592680 @default.
- W2969132911 hasConcept C207001950 @default.
- W2969132911 hasConcept C2775915353 @default.
- W2969132911 hasConcept C2776521421 @default.
- W2969132911 hasConcept C2776882836 @default.
- W2969132911 hasConcept C2778198053 @default.
- W2969132911 hasConcept C2778527774 @default.
- W2969132911 hasConcept C2778938600 @default.
- W2969132911 hasConcept C2779984381 @default.
- W2969132911 hasConcept C2781092963 @default.
- W2969132911 hasConcept C2781121420 @default.
- W2969132911 hasConcept C2908929049 @default.
- W2969132911 hasConcept C3156946 @default.
- W2969132911 hasConcept C71924100 @default.
- W2969132911 hasConcept C86803240 @default.
- W2969132911 hasConcept C98274493 @default.
- W2969132911 hasConceptScore W2969132911C118487528 @default.
- W2969132911 hasConceptScore W2969132911C126322002 @default.
- W2969132911 hasConceptScore W2969132911C134018914 @default.
- W2969132911 hasConceptScore W2969132911C150903083 @default.
- W2969132911 hasConceptScore W2969132911C170493617 @default.
- W2969132911 hasConceptScore W2969132911C185592680 @default.
- W2969132911 hasConceptScore W2969132911C207001950 @default.
- W2969132911 hasConceptScore W2969132911C2775915353 @default.
- W2969132911 hasConceptScore W2969132911C2776521421 @default.
- W2969132911 hasConceptScore W2969132911C2776882836 @default.
- W2969132911 hasConceptScore W2969132911C2778198053 @default.
- W2969132911 hasConceptScore W2969132911C2778527774 @default.
- W2969132911 hasConceptScore W2969132911C2778938600 @default.
- W2969132911 hasConceptScore W2969132911C2779984381 @default.